Business
Rockwell Medical, Inc. Provides Business Update
-- Continued progress for Triferic® portfolio ---- 77% increase in the number of clinics under contract -- WIXOM, Mich., Feb. 27, 2020 (GLOBE NEWSWIRE) --
About this update from Rockwell Medical, Inc.
[{"type":"text","content":"-- Continued progress for Triferic® portfolio ---- 77% increase in the number of clinics under contract --\n WIXOM, Mich., Feb. 27, 2020 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (NASDAQ:RMTI) (“Rockwell Medical” or the \"Company\"), a biopharmaceutical company dedicated to transforming anemia management and improving outcomes for patients around the world, today provided a business update and information related to the launch of Dialysate Triferic® (ferric pyrophosphate citrate). Key Business Updates and Highlights for the Quarter Ended December 31, 2019 77% sequential-quarter increase in the number of clinics contracted to purchase Dialysate Triferic, and a 67% increase in the number of annualized treatments under contract.75% of the clinics that completed an Evaluation Program for Dialysate Triferic in the fourth quarter have converted to commercial customers.Signed an agreement with a Medium-Sized Dialysis Organization (MDO) for the purchase of Dialysate Triferic in late November 2019. As of December 31, 2019, five clinics within this MDO had purchased Dialysate Triferic, and Rockwell Medical expects clinic adoption to accelerate during the first half of 2020. Approximately 160 clinics within the MDO are candidates for Dialysate Triferic.Strengthened and expanded medical capabilities, including the hiring of Marc Hoffman, MD, as Chief Medical Officer, appointment of Russell Ellison, MD, to the Board of Directors, and the appointment of three world-renowned nephrologists to the Company’s Medical Advisory Board. “We are encouraged by the positive trends in adoption we are seeing as we roll out the Triferic platform in the U.S. The recent signing of a Medium-Sized Dialysis Organization is a meaningful accomplishment, as it extends our reach in transforming anemia management for hemodialysis patients and represents a sizable sales opportunity. To support our commercial activities, we continue to build out our medical capabilities through the additions of prominent anemia and ESRD experts to our management team, Board of Directors and Medical Advisory Board. Our near-term efforts remain focused on driving adoption of our innovative therapeutic and to ensuring that Triferic is available to the patients who can benefit,” stated Stuart Paul, President and Chief Executive Officer of Rockwell Medical. Rockwell Medical will host its q...